Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Afinitor,AfinitorStudy001,2022,USA,MDV,350,68,35,65,27.5,42,85,15,18,32,25,25,55,20,15,10,20,35,45,18,8,5,12,7,22,38,45,Docetaxel + Carboplatin,AC (Doxorubicin + Cyclophosphamide),AC-T (Doxorubicin + Cyclophosphamide followed by Paclitaxel),TC (Docetaxel + Cyclophosphamide),25,15,10,30,40,50,15,45,40,60,2
Afinitor,AfinitorStudy002,2023,Canada,Claim Database,420,72,40,60,28.1,38,78,18,20,30,28,22,52,22,16,10,22,33,45,20,10,6,14,8,20,40,42,"FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide)",Taxol,"CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)","EC (Epirubicin, Cyclophosphamide)",20,18,12,32,42,52,18,42,40,62,3
Afinitor,AfinitorStudy003,2022,UK,MDV,280,65,30,70,26.8,45,90,12,15,35,20,30,60,18,12,10,25,30,45,15,7,4,10,6,25,35,48,Carboplatin + Paclitaxel,EC,Taxotere,Cyclophosphamide,22,13,15,28,38,48,12,48,40,58,2.5
Afinitor,AfinitorStudy004,2023,Germany,Claim Database,480,70,38,62,27.9,40,80,16,19,31,26,24,53,21,17,9,21,34,45,19,9,5,13,7,21,39,43,Docetaxel + Doxorubicin + Cyclophosphamide,Epirubicin + Cyclophosphamide,Fluorouracil + Epirubicin + Cyclophosphamide,Cyclophosphamide + Methotrexate + Fluorouracil,21,17,11,31,41,51,17,43,40,61,2.8
